Lobular carcinoma in situ

European Journal of Cancer Prevention

Volumn 17, Issue 4, 2008, Pages 312-316

  Afonso, Nelia ^a,b   Bouwman, David ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Breast cancer prevention; Breast cancer risk; Lobular carcinoma in situ

Indexed keywords

ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; BREAST EXAMINATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; ENDOMETRIUM CANCER; FOLLOW UP; HOT FLUSH; HUMAN; LOBULAR CARCINOMA IN SITU; MASTECTOMY; NEEDLE BIOPSY; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; UTERUS CANCER; VENOUS THROMBOEMBOLISM; ADULT; AGE; AGED; BREAST TUMOR; CANCER STAGING; CARCINOMA IN SITU; CELL TRANSFORMATION; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; METHODOLOGY; MIDDLE AGED; MONITORING; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRECANCER; PROGNOSIS; RISK ASSESSMENT; SURVIVAL;

ADULT; AGE FACTORS; AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 49649086737     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3282f75e5d     Document Type: Review

References (57)

1. Akashi-Tanaka S, Fukutomi T, Nanasawa T, Matsuo K, Hasegawa T, Tsuda H (2000). Treatment of noninvasive carcinoma: fifteen-year results at the National Cancer Center Hospital in Tokyo. Breast Cancer 7:341-344.
2. Alpers CE, Wellings SR (1985). The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 16:796-807.
3. Andersen JA (1977). Lobular carcinoma in situ of the breast. An approach to rational treatment. Cancer 39:2597-2602.
4. Anderson BO, Rinn K, Georgian-Smith D, Lawton T, Li CI, Moe RE (2002). Lobular carcinoma in situ. In: Silverstein MJ, Recht A, Lagios MD, editors. Ductal carcinoma of the breast. 2nd ed. Philadelphia: Lippincott. pp. 615-634.
5. Beute BJ, Kalisher L, Hutter RVP (1991). Lobular carcinoma in situ of the breast: clinical pathologic and mammographic features. AJR Am J Roentgenol 157:257-265.
6. Black WC, Nease RF Jr, Tosteson AN (1995). Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 87:720-731.
7. Bland KI, Menck HR, Scott-Conner CE, Morrow M, Winchester DJ, Winchester DP (1998). The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer 83: 1262-1273.
8. Brogi E, Robson M, Panageas KS, Casadio C, Ljung BM, Montgoamery L (2003). Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study. Cancer 98:2170-2176.
9. Carson W, Sanchez-Forgach E, Stomper P, Penetrante R, Tsangaris TN, Edge SB (1994). Lobular carcinoma in situ: observation without surgery as an appropriate therapy. Ann Surg Oncol 1:141-146.
10. Chuba PJ, Hamre MR, Severson RK, Lucas D, Shamsa F, Aref A (2005). Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534-5541.
11. Cutuli B, deLafontan B, Quetin P, Mery E (2005). Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ? Eur J Cancer 41:380-385.
12. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al.; International Breast Cancer Intervention Study I Investigators (2007). Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272-282.
13. Diagnosis and Management of Specific Breast Abnormalities. Summary, Evidence Report/Technology Assessment: Number 33. AHRQ Publication No. 01-E045, April 2001. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epcsums/abnorsum.htm
14. Dunn BK, Ford LG (2007). Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Eur J Cancer Prev 16:232-242.
15. Elsheik TM, Silverman JF (2005). Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol 29:534-543.
16. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
17. Fondrinier E, Lorimer G, Guerin-Boblet V, Bertrand AF, Mayras C, Dauver N (2002). Breast microcalcifications: multivariate analysis of radiological and clinical factors for carcinoma. World J Surg 26:290-296.
18. Foote FW, Stewart FE (1941). Lobular carcinoma in situ, a rare form of mammary cancer. Am J Pathol 17:491-505.
19. Foster MC, Helvie MA, Gregory NE, Rebner M, Nees AV, Paramagul C (2004). Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? Radiology 231:813-819.
20. Frantz VK, Pickren JW, Melcher GW, Auchincloss H Jr (1951). Incidence of chronic cystic disease in so-called 'normal breasts'; a study based on 225 postmortem examinations. Cancer 4:762-783.
21. Frykberg ER (1999). Lobular carcinoma in situ of the breast. Breast J 5: 296-303.
22. Georgian-Smith D, Lawton TJ (2001). Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. Am J Roentgenol 176: 1255-1259.
23. Gump F, Dinne D, Schwartz GF (1998). Current treatment for lobular carcinoma in situ. Ann Surg Oncol 5:33-36.
24. Haagensen CD, Lane N, Lattes R, Bodian C (1978). Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 42:737-769.
25. Haagensen CD, Bodian C, Haagensen DE (1981). Lobular neoplasia (lobular carcinoma in situ) breast carcinoma: risk and detection. Philadelphia: WB Saunders.
26. Jolly S, Kestin LL, Goldstein NS, Vicini FA (2006). The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 66:365-371.
27. Kramer WM, Rush BF Jr (1973). Mammary duct proliferation in the elderly. A histopathologic study. Cancer 31:130-137.
28. Lakhani SR (2003). The diagnosis and management of preinvasive breast disease: current challenges, future hopes. Breast Cancer Res 5:248-249.
29. Lakhani SR, Audretsch W, Cleton-Jensen AM, Cutuli B, Ellis I, Eusebi V, et al.; EUSOMA (2006). The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS) ? Eur J Cancer 42: 2205-2211.
30. Li CI, Anderson BO, Daling JR, Moe RE (2002). Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat 75:259-268.
31. Li CI, Daling JR, Malone KE (2005). Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 4:1008-1011.
32. Li CI, Malone KE, Saltzman BS, Daling JR (2006). Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 106:2104-2112.
33. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA (1997). Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 6:297-301.
34. Maucort-Boulch D, Roy P (2006). Modeling the effect of tamoxifen hemoprevention on long-term mortality in white women at high risk of breast cancer. Eur J Cancer Prev 15:347-352.
35. Newman W (1963). In situ lobular carcinoma of the breast: report of 26 women with 32 cancers. Ann Surg 157:591-599.
36. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA (1987). Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 56:814-819.
37. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA (1993). Lobular carcinoma in situ of the female breast: short term results of a prospective nationwide study. Am J Surg Pathol 17:14-21.
38. Page DL, Dupont WD, Rogers LW, Rados MS (1985). Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55: 2698-2708.
39. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW (1991). Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22:1232-1239.
40. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF (2003). A typical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 361:125-129.
41. Pope TL, Fechner RE, Wilhem MC, Wanebo HJ, DeParedes ES (1988). Lobular carcinoma in situ of the breast: mammographic features. Radiology 168: 63-66.
42. Port ER, Montgomery LL, Heerdt AS, Borgen PI (2001). Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8:580-585.
43. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, et al. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:981-983.
44. Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW Jr (1978). Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 2:225-251.
45. Rosen PP, Senie R, Schottenfeld D, Ashikari R (1979). Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg 189:377-382.
46. Salvadori B, Bartoli C, Zurrida S, Delledonne V, Squicciarini P, Rovini D, Barletta L (1991). Risk of invasive cancer in women with lobular carcinoma in situ of the breast. Eur J Cancer 27:35-37.
47. Sapino A, Frigerio A, Peterse JL, Arisio R, Coluccia C, Bussolati G (2000). Mammographically detected in situ lobular carcinoma of the breast. Virchows Arch 436:421-430.
48. Shin SJ, Rosen PP (2002). Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med 126:697-701.
49. Sigal-Zafrani B, Vincent-Salmon A, Penault-Llorca F, Sastre-Garau X (2003). Lobular neoplasia. Ann Pathol 23:547-553.
50. Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP (2002). Clinical, histopathologic and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol 15: 1044-1050.
51. Sonnenfeld MR, Frenna TH, Weidner N, Meyer JE (1991). Lobular carcinoma in situ: mammographic pathologic correlation of results of needle-directed biopsy. Radiology 181:363-367.
52. Tavassoli FA, Devillee P, editors. (2003). World Health Organization Classification of tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press.
53. Urban J (1967). Bilaterality of cancer of the breast: Biopsy of the opposite breast. Cancer 20:1867-1870.
54. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. (2006). National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741.
55. Wheeler JE, Enterline HT, Roseman JM, Tomasulo JP, McIlvaine CH, Fitts WT Jr, Kirshenbaum J (1974). Lobular carcinoma in situ of the breast. Long-term followup. Cancer 34:554-563.
56. Zheng T, Holford TR, Chen Y, Jones BA, Flannery J, Boyle P (1997). Times trend of female breast carcinoma in situ by race and histology in Connecticut USA. Eur J Cancer 33:96-100.
57. Zurrida S, Bartoli C, Galimberti V, Raselli R, Barletta L (1996). Interpretation of risk associated with the unexpected finding of lobular carcinoma in situ. Ann Surg Oncol 3:57-61.